|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Supplemental Table 3: Baseline Weight Promoting Medication Utilization by Weight Class** |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |
| **Medications** | **Underweight** | **Normal Weight** | **Overweight** | **Class I Obesity** | **Class II Obesity** | **Class III Obesity** | **All women  in sample** |
| **(BMI ≤ 18.5)** | **(BMI 18.5-24.9)** | **(BMI 25-29.9)** | **(BMI 30-34.9)** | **(BMI 35- 39.9)** | **(BMI ≥ 40)** |  |
| **N=910** | **N=31,282** | **N=26,031** | **N=11,554** | **N=4,104** | **N=2,371** | **N=76,252** |
| **Antidepressants** | 49 5.4% | 1,696 5.4% | 1,770 6.8% | 943 8.2% | 415 10.1% | 274 11.6% | 5,147 6.7% |
| Selective Serotonin Reuptake Inhibitors (SSRIS) | 25 2.7% | 849 2.7% | 928 3.6% | 522 4.5% | 239 5.8% | 160 6.7% | 2,723 3.6% |
| Tricyclic Agents | 22 2.4% | 786 2.5% | 793 3% | 403 3.5% | 179 4.4% | 103 4.3% | 2,286 3% |
| Misc.Antidepressants | 5 0.5% | 122 0.4% | 121 0.5% | 69 0.6% | 28 0.7% | 32 1.3% | 377 0.5% |
| **Antipsychotics** | 0 0% | 7 0.02% | 10 0.04% | 1 0.01% | 2 0.05% | 1 0.04% | 21 0.03% |
| Benzisoxazoles | 0 0% | 7 0.02% | 10 0.04% | 1 0.01% | 2 0.05% | 1 0.04% | 21 0.03% |
| Thienbenzodiazepines | 0 0% | 0 0% | 0 0% | 0 0% | 0 0% | 0 0% | 0 0% |
| **Beta Blockers** | 52 5.7% | 1,889 6% | 2,136 8.2% | 1,253 10.8% | 432 10.5% | 273 11.5% | 6,035 7.9% |
| Beta Blockers Cardio-Selective | 35 3.8% | 1,344 4.3% | 1,627 6.3% | 983 8.5% | 342 8.3% | 193 8.1% | 4,524 5.9% |
| Beta Blockers Non-Selective | 17 1.9% | 546 1.7% | 511 2% | 272 2.4% | 90 2.2% | 80 3.4% | 1,516 2% |
| **OTC Insulin** | 1 0.1% | 98 0.3% | 177 0.7% | 150 1.3% | 122 3% | 101 4.3% | 649 0.9% |
| **Glucocorticosteroids** | 19 2.1% | 328 1% | 335 1.3% | 159 1.4% | 78 1.9% | 38 1.6% | 957 1.3% |
|  |  |  |  |  |  |  |  |
| Data are numbers and column percentages |  |  |  |  |  |  |  |

OTC- Over the Counter